Takeshi Osonoi

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Hiddo J.L. Heerspink, Hans‐Henrik Parving, Dennis L. Andress et al. · The Lancet · 2019 · 589 citations · Full text

Urology, Renal Disease, Renal Events +7

Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial

Yuichiro Yamada, Hideki Katagiri, Yoshiyuki Hamamoto et al. · The Lancet Diabetes & Endocrinology · 2020 · 204 citations · Full text

Pioneer 9, Diabetes Management, Diabetes +9

Relationship between urinary sodium excretion and pioglitazone‐induced edema

A Nakamura, Takeshi Osonoi, Yasuo Terauchi · Journal of Diabetes Investigation · 2010 · 198 citations · Full text

Hypertension, Electrolyte Disorder, Pharmacotherapy +18

Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial

Daisuke Yabe, Jiro Nakamura, Hideaki Kaneto et al. · The Lancet Diabetes & Endocrinology · 2020 · 182 citations

Diabetes Management, Cardiovascular Disease, Medicine +8

Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A)

Tomoya Mita, Naoto Katakami, Hidenori Yoshii et al. · Diabetes Care · 2015 · 162 citations